Elexacaftor / tezacaftor / ivacaftor vs Ivacaftor

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Cystic Fibrosis

Shared mechanism: CFTR · full Cystic Fibrosis pipeline

Elexacaftor / tezacaftor / ivacaftor · Trikafta

Marketed by Vertex Pharmaceuticals

Approved in Cystic Fibrosissmall molecule
Reliable signal

NCT03525444 · Phase 3 · completed

Trial 1 in the TRIKAFTA label was a 24-week, randomized, double-blind, placebo-controlled Phase 3 trial in 405 people aged 12 and older with one F508del variant and a minimal function variant. The single primary endpoint was the absolute change in percent predicted FEV1 at Week 4. TRIKAFTA improved it by 13.8 percentage points more than placebo (95% CI 12.1 to 15.4, P<0.0001), so the primary endpoint was met. Sources: the FDA label (TRIKAFTA) and the CT.gov posted results.

Next expected readout: April 2027 · NCT05331183 (registry estimate)

Reported efficacy

Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) (From Baseline at Week 4): Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results). (met)

Result source: NCT03525444

Ivacaftor · Kalydeco

Marketed by Vertex Pharmaceuticals

Approved in Cystic Fibrosissmall molecule
Partial signal

NCT00909532 · Phase 3 · completed

The study was randomized and quadruple-blinded, compared ivacaftor with placebo, and enrolled 167 participants; its objective primary endpoint, percent-predicted FEV1, was met with a statistically significant treatment difference. However, the supplied registry record does not report a power or sample-size calculation, so the trial receives a moderate grade despite its otherwise strong design.

Reported efficacy

Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1) (met)

Result source: NCT00909727

Results for Cystic Fibrosis

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Elexacaftor / tezacaftor / ivacaftor
Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results). NCT03525444 · Phase 3 · design grade: strong · publication or press release
Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results). NCT03525548 · Phase 3 · design grade: strong · publication or press release
Ivacaftor
Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7) NCT00909532 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1) NCT00909727 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elexacaftor / tezacaftor / ivacaftor's landscape · Ivacaftor's landscape